----item----
version: 1
id: {DAEC748C-0E4A-456E-A822-D391AA4A45F7}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/13/Blend Therapeutics appoints CEO
parent: {9FB0ADDF-A2A3-44A3-B361-887553556EB6}
name: Blend Therapeutics appoints CEO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: f929c6dc-2eed-41e2-852a-48f7923a905a

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 31

Blend Therapeutics appoints CEO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 31

Blend Therapeutics appoints CEO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1232

<p>Watertown, Massachusetts-based Blend Therapeutics, a biopharmaceutical company developing two classes of targeted anti-cancer medicines for the treatment of patients with solid tumor cancers, has named Drew Fromkin president and CEO. </p><p>Mr Fromkin was previously president and CEO of Clinical Data until its acquisition by Forest Laboratories. Prior to Clinical Data, Mr Fromkin was president and CEO of DoctorQuality (acquired by Quantros), president, CEO and director of Endo Surgical Devices, and corporate vice-president of business development for Merck-Medco, a wholly-owned subsidiary of Merck & Co.</p><p>Now at Blend he is charged with leading the company as it advances its pipeline of anti-cancer therapeutics into human clinical trials. Blend plans to file two investigational new drug (IND) applications with the US FDA in 2Q 2015 for its novel personalized cisplatin prodrug, BTP-114; and in early 2016 for its first targeted drug candidate from its Pentarin platform, BTP-277. Pentarins are comprised of a miniaturized biologic drug conjugate (mBDC) in a polymeric nanoparticle. Blend creates novel mBDCs comprised of a targeting ligand conjugated to a potent cell-killing agent through a chemical linker. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 241

<p>Watertown, Massachusetts-based Blend Therapeutics, a biopharmaceutical company developing two classes of targeted anti-cancer medicines for the treatment of patients with solid tumor cancers, has named Drew Fromkin president and CEO. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 31

Blend Therapeutics appoints CEO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150413T160000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150413T160000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150413T160000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028413
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 31

Blend Therapeutics appoints CEO
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357764
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042328Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

f929c6dc-2eed-41e2-852a-48f7923a905a
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042328Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
